Öz
Özet
Metabolik sendrom obezite, dislipidemi, hiperglisemi ve hipertansiyon gibi hastalıkların toplamından oluşur. Metabolik sendrom bileşenlerinin çoğu tümör gelişimi ile bağlantılıdır. Metabolik sendrom ve visseral obezitenin genel populasyonda sıklık ve yaygınlığı giderek artmaktadır. Obezite son zamanlarda kanserlerin çoğunda mortalite ile bağlantılıdır. Kolorektal kanser önemli bir halk sağlığı problemidir. Son raporlar metabolik sendromlu bireylerde kolon veya rektum kanseri riskinin yüksek olduğunu göstermiştir. Metabolik sendrom ve kolorektal kanser arasındaki bağlantının patofizyolojik mekanizması çoğunlukla abdominal obezite ve insülin direnci ile ilişkilidir. Beslenme, egzersiz ve stresi azaltmayı kapsayan multidisipliner bir yaklaşım insülin direncini sınırlamada ve kanser sonuçlarını iyileştirmede çok önemli bir fırsat olabilir.
Anahtar sözcükler: Metabolik sendrom, kanser, insülin direnci, obezite
Abstract
Metabolic syndrome consists of a cluster of diseases including obesity, dyslipidemia, hyperglycemia and hypertension. Most of the components of metabolic syndrome have been associated with the development of neoplasm. The metabolic syndrome and visceral obesity have an increasing prevalence and incidence in the general population. Obesity has recently been linked to mortality in the majority of cancers. Colorectal cancer is an important public health problem. Recent reports in individuals with metabolic syndrome showed a high risk of colon or rectal cancer. The pathophysiological mechanism that links metabolic syndrome and colorectal cancer is mostly related to abdominal obesity and insulin resistance. A multidisciplinary approach involving nutrition, exercise, and stress reduction may be an opportunity to limit the insulin-resistant state and improve cancer outcomes.
Keywords: Metabolic syndrome, cancer, insulin resistance, obesity
Anahtar Kelimeler
Kaynakça
- Pais R, Silaghi H, Silaghi AC, Rusu ML, Dumitrascu DL. Metabolic syndrome and risk of subsequent colorectal cancer. World J Gastroenterol 2009; 15: 5141-8.
- Gönüllü G, Kahraman H, Bedir A, Bektas A, Yücel İ. Association between adiponectin, resistin, insulin resistance, and colorectal tumors. Int J Colorectal Dis 2010; 25: 205-12.
- Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F; Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-52.
- Çengel A. Kadınlarda kardiyovasküler risk faktörleri. Türk Kardiyol Dern Arş 2010; 1: 17-24.
- Lee GE, Park HS, Yun KE, Jun SH, Kim HK, Cho Sİ, Kim JH. Association between BMI and metabolic syndrome and adenomatous colonic polyps in Korean men. Obesity 2008; 16: 1434-9.
- Trevisan M, Liu J, Muti P, Misciagna G, Menotti A, Fucci F; Risk Factors and Life Expectancy Research Group. Markers of insulin resistance and colorectal cancer mortality. Cancer Epidemiol Biomarkers Prev 2001; 10: 937-41.
- Boyd DB. Insulin and cancer. Integr Cancer Ther 2003; 2: 315-29.
- Giovannucci E. Insulin, insulin-like growth factors and colon cancer: a review of the evidence. J Nutr 2001; 131: 3109-20.
- Onat A, Hergenç G, Can G. Prospective validation in identical Turkish cohort of two metabolic syndrome definitions for predicting cardiometabolic risk and selection of most appropriate definition. Anadolu Kardiyol Derg 2007; 7: 29-34.
- Kozan O, Oğuz A, Abacı A, Erol C, Öngen Z, Temizhan A, Çelik S. Prevalence of the metabolic syndrome among Turkish adults. Eur J Clin Nutr 2007; 61: 548- 53.
- Garow D. Metabolic syndrome is a risk factor for colorectal cancer in the United States. American College of Gastroenterology 2008; Annual Scientific Meeting.
- Khaw KT, Wareham N, Bingham S, Luben R, Welch A, Day N. Preliminary communication: glycated hemoglobin, diabetes, and incident colorectal cancer in men and women: a prospective analysis from the European prospective investigation into cancer-Norfolk study. Cancer Epidemiol Biomarkers Prev 2004; 13: 915-9.
- Saydah SH, Platz EA, Rifai N, Pollak MN, Brancati FL, Helzlsouer KJ. Association of markers of insulin and glucose control with subsequent colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 2003; 12: 412-8.
- Moore LL, Bradlee ML, Singer MR, Splansky GL, Proctor MH, Ellison RC, Kreger BE. BMI and waist circumference as predictors of lifetime colon cancer risk in Framingham Study adults. Int J Obes Relat Metab Disord 2004; 28: 559- 67.
- Erarslan E, Turkay C, Koktener A, Koca C, Uz B, Bavbek N. Association of visceral fat accumulation and adiponectin levels with colorectal neoplasia. Dig Dis Sci 2009; 54: 862-8.
- Jee SH, Ohrr H, Sull JW, Yun JE, Ji M, Samet JM. Fasting serum glucose level and cancer risk in Korean men and women. JAMA 2005; 293: 194-202.
- Komninou D, Ayonote A, Richie JP Jr, Rigas B. Insulin resistance and its contribution to colon carcinogenesis. Exp Biol Med (Maywood) 2003; 228: 396- 405.
- Ealey KN, Archer MC. Elevated circulating adiponectin and elevated insulin sensitivity in adiponectin transgenic mice are not associated with reduced susceptibility to colon carcinogenesis. Int J Cancer 2009; 124: 2226-30.
- Caan BJ, Coates AO, Slattery ML, Potter JD, Quesenberry CP Jr, Edwards SM. Body size and the risk of colon cancer in a large case-control study. Int J Relat Metab Disord 1998; 22: 178-84.
- Murphy TK, Calle EE, Rodriguez C, Kahn HS, Thun MJ. Body mass index and colon cancer mortality in a large prospective study. American Journal of Epidemiology 2000; 152: 847-54.
- Wei EK, Giovannucci E, Fuchs CS, Willett WC, Mantzoros CS. Low plasma adiponectin levels and risk of colorectal cancer in men: A prospective study. J Natl Cancer İnst 2005; 97: 1688-94.
- Tamakoshi K, Toyoshima H, Wakai K, Kojima M, Suzuki K, Watanabe Y, Hayakawa N, Yatsuya H, Kondo T, Tokudome S, Hashimoto S, Suzuki S, Kawado M, Ozasa K, Ito Y, Tamakoshi A. Leptin is associated with an increased female colorectal cancer risk: a nested case-control study in Japan. Oncology 2005; 68: 454-61.
- Nikiteas NI, Tzanakis N, Gazouli M, Rallis G, Daniilidis K, Theodoropoulos G, Kostakis A, Peros G. Serum IL-6, TNFalpha and CRP levels in Greek colorectal cancer patients: prognostic implications. World J Gastroenterol 2005; 11: 1639- 43.
- Fajas L, Debril MB, Auwerx J. Peroxisome proliferator-activated receptor- gamma: from adipogenesis to carcinogenesis. J Mol Endocrinol 2001; 27: 1-9.
Öz
Metabolik sendrom obezite, dislipidemi, hiperglisemi ve hipertansiyon gibi hastalıkların toplamından oluşur. Metabolik sendrom bileşenlerinin çoğu tümör gelişimi ile bağlantılıdır. Metabolik sendrom ve visseral obezitenin genel populasyonda sıklık ve yaygınlığı giderek artmaktadır. Obezite son zamanlarda kanserlerin çoğunda mortalite ile bağlantılıdır. Kolorektal kanser önemli bir halk sağlığı problemidir. Son raporlar metabolik sendromlu bireylerde kolon veya rektum kanseri riskinin yüksek olduğunu göstermiştir. Metabolik sendrom ve kolorektal kanser arasındaki bağlantının patofizyolojik mekanizması çoğunlukla abdominal obezite ve insülin direnci ile ilişkilidir. Beslenme, egzersiz ve stresi azaltmayı kapsayan multidisipliner bir yaklaşım insülin direncini sınırlamada ve kanser sonuçlarını iyileştirmede çok önemli bir fırsat olabilir
Anahtar Kelimeler
Kaynakça
- Pais R, Silaghi H, Silaghi AC, Rusu ML, Dumitrascu DL. Metabolic syndrome and risk of subsequent colorectal cancer. World J Gastroenterol 2009; 15: 5141-8.
- Gönüllü G, Kahraman H, Bedir A, Bektas A, Yücel İ. Association between adiponectin, resistin, insulin resistance, and colorectal tumors. Int J Colorectal Dis 2010; 25: 205-12.
- Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F; Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-52.
- Çengel A. Kadınlarda kardiyovasküler risk faktörleri. Türk Kardiyol Dern Arş 2010; 1: 17-24.
- Lee GE, Park HS, Yun KE, Jun SH, Kim HK, Cho Sİ, Kim JH. Association between BMI and metabolic syndrome and adenomatous colonic polyps in Korean men. Obesity 2008; 16: 1434-9.
- Trevisan M, Liu J, Muti P, Misciagna G, Menotti A, Fucci F; Risk Factors and Life Expectancy Research Group. Markers of insulin resistance and colorectal cancer mortality. Cancer Epidemiol Biomarkers Prev 2001; 10: 937-41.
- Boyd DB. Insulin and cancer. Integr Cancer Ther 2003; 2: 315-29.
- Giovannucci E. Insulin, insulin-like growth factors and colon cancer: a review of the evidence. J Nutr 2001; 131: 3109-20.
- Onat A, Hergenç G, Can G. Prospective validation in identical Turkish cohort of two metabolic syndrome definitions for predicting cardiometabolic risk and selection of most appropriate definition. Anadolu Kardiyol Derg 2007; 7: 29-34.
- Kozan O, Oğuz A, Abacı A, Erol C, Öngen Z, Temizhan A, Çelik S. Prevalence of the metabolic syndrome among Turkish adults. Eur J Clin Nutr 2007; 61: 548- 53.
- Garow D. Metabolic syndrome is a risk factor for colorectal cancer in the United States. American College of Gastroenterology 2008; Annual Scientific Meeting.
- Khaw KT, Wareham N, Bingham S, Luben R, Welch A, Day N. Preliminary communication: glycated hemoglobin, diabetes, and incident colorectal cancer in men and women: a prospective analysis from the European prospective investigation into cancer-Norfolk study. Cancer Epidemiol Biomarkers Prev 2004; 13: 915-9.
- Saydah SH, Platz EA, Rifai N, Pollak MN, Brancati FL, Helzlsouer KJ. Association of markers of insulin and glucose control with subsequent colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 2003; 12: 412-8.
- Moore LL, Bradlee ML, Singer MR, Splansky GL, Proctor MH, Ellison RC, Kreger BE. BMI and waist circumference as predictors of lifetime colon cancer risk in Framingham Study adults. Int J Obes Relat Metab Disord 2004; 28: 559- 67.
- Erarslan E, Turkay C, Koktener A, Koca C, Uz B, Bavbek N. Association of visceral fat accumulation and adiponectin levels with colorectal neoplasia. Dig Dis Sci 2009; 54: 862-8.
- Jee SH, Ohrr H, Sull JW, Yun JE, Ji M, Samet JM. Fasting serum glucose level and cancer risk in Korean men and women. JAMA 2005; 293: 194-202.
- Komninou D, Ayonote A, Richie JP Jr, Rigas B. Insulin resistance and its contribution to colon carcinogenesis. Exp Biol Med (Maywood) 2003; 228: 396- 405.
- Ealey KN, Archer MC. Elevated circulating adiponectin and elevated insulin sensitivity in adiponectin transgenic mice are not associated with reduced susceptibility to colon carcinogenesis. Int J Cancer 2009; 124: 2226-30.
- Caan BJ, Coates AO, Slattery ML, Potter JD, Quesenberry CP Jr, Edwards SM. Body size and the risk of colon cancer in a large case-control study. Int J Relat Metab Disord 1998; 22: 178-84.
- Murphy TK, Calle EE, Rodriguez C, Kahn HS, Thun MJ. Body mass index and colon cancer mortality in a large prospective study. American Journal of Epidemiology 2000; 152: 847-54.
- Wei EK, Giovannucci E, Fuchs CS, Willett WC, Mantzoros CS. Low plasma adiponectin levels and risk of colorectal cancer in men: A prospective study. J Natl Cancer İnst 2005; 97: 1688-94.
- Tamakoshi K, Toyoshima H, Wakai K, Kojima M, Suzuki K, Watanabe Y, Hayakawa N, Yatsuya H, Kondo T, Tokudome S, Hashimoto S, Suzuki S, Kawado M, Ozasa K, Ito Y, Tamakoshi A. Leptin is associated with an increased female colorectal cancer risk: a nested case-control study in Japan. Oncology 2005; 68: 454-61.
- Nikiteas NI, Tzanakis N, Gazouli M, Rallis G, Daniilidis K, Theodoropoulos G, Kostakis A, Peros G. Serum IL-6, TNFalpha and CRP levels in Greek colorectal cancer patients: prognostic implications. World J Gastroenterol 2005; 11: 1639- 43.
- Fajas L, Debril MB, Auwerx J. Peroxisome proliferator-activated receptor- gamma: from adipogenesis to carcinogenesis. J Mol Endocrinol 2001; 27: 1-9.
Ayrıntılar
| Birincil Dil | İngilizce |
|---|---|
| Bölüm | Derlemeler |
| Yazarlar | |
| Yayımlanma Tarihi | 21 Aralık 2012 |
| Yayımlandığı Sayı | Yıl 2012Cilt: 34 Sayı: 3 |